We compared two officially recommended methods for determination of aspartate aminotransferase (EC 2.6.1.1): that of the International Federation of Clinical Chemistry (IFCC) and that of the Deutsche Gesellschaft f#{252}r Klinische Chemie (DGKC). We used automated enzyme analyzers, initiating the reactions with 2-oxoglutarate. Normal values, 10-30 U/L (IFCC) and 7-18 U/L (DGKC), were apparently insensitive to intra-individual variations. Samples obtained from patients with heart disease showed a markedly different amount of activation with pyndoxal phosphate as compared with samples from other patient categories. Ratios for aspartate aminotransferase/alanine aminotransferase, as used in the differentiation of liver disease, can still be used with either method for determination of aspartate aminotransferase.
glutamate dehydrogenase (GLDH). All contaminant catalytic activities were measured as stipulated in references 2 and 3.
Apparatus.
For spectrophotometric measurements we used automated Eppendorf 5020 and 5040 enzyme analyzers (EppendorfGeratebau, Netheler & Hinz, Hamburg, F.R.G.). pH was measured at 25 and 30#{176}C with an IL 305 pH meter (Instrumentation Laboratory,
S.P.A., Dugano, Italy) and an
ElKay OHP-1433-U combined pH reference electrode (ElKay Products Inc., Worcester, MA 01613). Samples. We analyzed 968 serum and plasma samples: 223 samples from apparently healthy hospital workers and 745 patients' samples, submitted to our laboratories for routine diagnostic investigation.
The patients' samples consisted of 225 samples from patients admitted to the coronary-care unit, 101 from patients suffering from liver disease, 61 from patients suffering from chronic renal disease, and 358 that could not be classified in one of the above-specified categories; the last three categories included both in-and outpatients. Blood was collected into evacuated blood-collection tubes (Venoject; Terumo Europe N.y., Haasrode, Belgium).Serum and heparinized plasma were obtained by centrifugation, and were stored at -20 #{176}C for no longer than five weeks.
Procedures

DGKC procedure.
ASAT and ALAT activities were measuredat 25#{176}C with the Eppendorf 5040 enzyme analyzer as follows: to 250 L of reagent, add 50 L of plasma or serum and preincubate for 7.5 mm. Startthe reaction by adding 50 L of 2-oxoglutarate to the pre-incubation mixture; after 80 s measure the absorbance at 334 nm (mercury line) for 20s. The final composition of the ASAT incubation mixture was: phosphate 80 mmol/L (pH 7.4 at 25#{176}C), iaspartate 200 mmol/L, 2-oxoglutarate 12 mmoIJL, f3-NADH 0.18 mmol/L, LDH 1200 U/L (at 25#{176}C), and MDH 600 U/L (at 25#{176}C).
The final composition of the ALAT incubation mixture was: phosphate 80 msnolfL(pH 7.4 at 25 #{176}C), ialanine 800 mmoIJL, 2-oxoglutarate 18 mmoIJL, f3-NADH 0.18 mmoIJL, and LDH 1200 U/L (at 25#{176}C).
IFCC and Bergmeyer et cii. (4) procedures.
ASAT and ALAT activities were measured at 30#{176}C with the Eppendorf 5020 analyzeras follows:
To 500 L of reagent add 50 L of plasma or serum and pre-incubate for 15 mm. Startthe reaction by adding 50 1zL of 2-oxoglutarate to the pre-incubation mixture including pyridoxal phosphate. After 26s, measure the absorbance at 334 nm (mercury line) for 154 s. No corrections for reagent and sample blanks were made.
The final composition of the ASAT incubation mixture was: Tris 80 mmol/L (pH 7.8 at 30#{176}C), 1.-aspartate 240 nimol/L,2-oxoglutarate 12 mmolJL, /3-NADH 0.18 mmol/L, pyridoxal phosphate 0.10 mmol/L, LDH 600 UIL (at 30#{176}C), and MDII 420 U/L (at 30#{176}C).
The final composition of the ALAT incubation mixture (4) was: Tris100 mmol/L (pH 7.5 at 30#{176}C), i-alanine 500 mmol/ 
Results
We observed no difference in ASAT results between 111 paired serum (y) and heparinized-plasma (x) samples, by Table 2 . Intra-and interindlvidual Variability of ASAT Figure 1 shows the correlation between results for all 968 samples, determined by both methods: y = 2.312, x -1.13, #{163} = 26.95,9 = 61.07, r2 = 0.821.
Intra-individual variability
Results for samples from 223 apparently healthy hospital workers are shown in Figure 2 . They showed no gaussian distribution.
We established the normal reference interval for ASAT by using nonparametric statistics, in particular, the 95th percentile for normal values. The reference interval for the DGKC method was 7-18 U/L and 10-30 U/L for the IFCC-
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based method. We observed no sex-related difference in normal values.
Statistical Analysis
We evaluated imprecision by repeatedassayof two pooled sera and two commercial preparations of ASAT of animal origin in an albumin matrix (Table 1) .
To assess the effect of the different methods on intra-and interindividual variability, we determined ASAT in samples from 16 apparently healthy volunteers.
Blood was sampled five times, once weekly, at 0800 hours; samples were promptly frozenand kept at -20 #{176}C until analyzed one to five weeks later. All samples were analyzed in one run. Results of these determinations are presented in Table 2 and Figure 3 . Terms are defined as in reference 6. SA2, the estimated analytical variance, by the present procedure consisted only of the within-runcomponent of variance. In this study we assumed this to be equal to the variance, as determined by analyzing control materials (from human and animal origin). In the calculations with SA, the values of SA are based on the CV for a particular range. We used the following CVs, determined from data on within-runprecision in control materials: By DGKC: for ASAT <10 UIL, CV = 12%; 10 UIL ASAT <12 U/L, CV = 8%; ASAT 12 UI L, CV = 5%. By IFCC: for ASAT <15 UIL, CV = 10%; 15 ASAT <25 U/L, CV = 5%; ASAT 25 UIL, CV = 3%. s,'2 is the estimated apparent intra-individual biological variance.
s2 is the estimated intra-individual biological variance: Determination of ASAT/ALAT ratios has been advocated in the differentiation of liver diseases (10). However, Lustig (11) states that ASAT/ALAT ratios are invalid after sample supplementation with pyridoxal phosphate. Figure 7 were determined by the DGKC procedure and by a procedure described by Bergmeyer et al. (4) . The latter procedure resembles the proposed IFCC procedure for ALAT (12), but NaHCO3 is included in the reagent. Clearly, ASAT/ALAT ratios obtained by the IFCC-based method are still usable. Our imprecision studies (Table 1) indicate that no improvement of precision can be expected by adopting the IFCCbased method, which is consistent with other results published by H#{216}rder et al. (13).
In conclusion, the IFCC-based method for determination of ASAT showed no impressive advantages over the established DGKC method. If a changeover is planned, clinicians should be properly informed, not only about changes in normal ranges but also about changes to be expected in data on pathological samples.
